Effect of testosterone administration on liver fat in older men with mobility limitation: Results from a randomized controlled trial

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 8, 2013, Pages 954-959

  Huang, Grace ^a   Bhasin, Shalender ^a   Tang, Elizabeth R ^b   Aakil, Adam ^b   Anderson, Stephan W ^b   Jara, Hernan ^b   Davda, Maithili ^a   Travison, Thomas G ^a,c   Basaria, Shehzad ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY   (United States)

Author keywords

Insulin resistance; Liver fat; Older men; Testosterone

Indexed keywords

TESTOSTERONE;

ADIPOSE TISSUE; AGED; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FATTY LIVER; HUMAN; INSULIN RESISTANCE; INSULIN RESISTANCE.; LIVER; LIVER FAT; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLDER MEN; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; WALKING DIFFICULTY;

INSULIN RESISTANCE.; LIVER FAT; OLDER MEN; TESTOSTERONE;

ADIPOSE TISSUE; AGED; AGED, 80 AND OVER; FATTY LIVER; HUMANS; INSULIN RESISTANCE; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MOBILITY LIMITATION; TESTOSTERONE;

EID: 84880556109     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls259     Document Type: Article

References (29)

1. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: An update. World J Gastroenterol. 2008;14:185-192. (Pubitemid 351314297)
2. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in non-obese nondiabetic subjects. Diabetes Care. 2008;31:562-568.
3. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: The Massachusetts Male Ageing Study. Clin Endocrinol (Oxf). 2006;65:125-131.
4. Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: A prospective cohort study. J Clin Endocrinol Metab. 2005;90:712-719. (Pubitemid 40279184)
5. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93:139-146.
6. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-906. (Pubitemid 43997730)
7. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828-837.
8. Lin H Y, Yu IC, Wang RS, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology. 2008;47:1924-1935.
9. Haider A, Gooren LJ, Padungtod P, Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes. 2010;118:167-171.
10. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011;34:729-749.
11. Chen T Y, Chen CL, Tsang LL, et al. Correlation between hepatic steatosis, hepatic volume, and spleen volume in live liver donors. Transplant Proc. 2008;40:2481-2483.
12. Stark DD, Bass NM, Moss AA, et al. Nuclear magnetic resonance imaging of experimentally induced liver disease. Radiology. 1983;148:743-751. (Pubitemid 13033798)
13. LeBrasseur NK, Lajevardi N, Miciek R, Mazer N, Storer TW, Bhasin S. Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (the TOM Trial): Design and methods. Contemp Clin Trials. 2009;30:133-140.
14. Travison TG, Basaria S, Storer TW, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66:1090-1099.
15. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109-122.
16. Lewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, Toouli J. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006;16:697-701. (Pubitemid 43874822)
17. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl. 2005;11:1481-1493. (Pubitemid 43072624)
18. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320-3325. (Pubitemid 37466894)
19. Nikolaenko L, Diaz-Arjonilla M, Laurel S, et al. Testosterone Reduces Non-Alcoholic Fatty Liver Disease (NAFLD) of Hypogonadism, (Abstract). Presented at: Program of the Annual 92th Meeting of the Endocrine Society; 2010; San Diego, CA.
20. Birzniece V, Meinhardt UJ, Handelsman DJ, Ho KK. Testosterone stimulates extra-hepatic but not hepatic fat oxidation (Fox): Comparison of oral and transdermal testosterone administration in hypopituitary men. Clin Endocrinol (Oxf). 2009;71:715-721.
21. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106:581-588. (Pubitemid 43157621)
22. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007;92:4254-4259. (Pubitemid 350074740)
23. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647-1659. (Pubitemid 44583955)
24. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab. 2002;87:136-143. (Pubitemid 34084682)
25. Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology. 2004;145:1842-1848. (Pubitemid 38402393)
26. Maffei L, Rochira V, Zirilli L, et al. A novel compound heterozygous mutation of the aromatase gene in an adult man: Reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic syndrome. Clin Endocrinol (Oxf). 2007;67:218-224. (Pubitemid 47076295)
27. Tian GX, Sun Y, Pang CJ, et al. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev. 2012;13:381-387.
28. Maggio M, Lauretani F, Ceda GP, et al. Estradiol and metabolic syndrome in older italian men: The InCHIANTI Study. J Androl. 2010;31:155-162.
29. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA. 2006;295:1288-1299. Institute